Malegra FXT 140mg / Sildenafil / fluoxetine

Description

The Malegra-FXT tablet is a mixture of two substances. It contains the popular sildenafil citrate, the cornerstone of most erectile dysfunction treatments, and fluoxetine, a specific serotonin reuptake inhibitor. Fluoxetine has been used as a stimulant but has also shown to improve premature ejaculation disorders. The mixture of these two drugs was created by the company Sunrise drug called Malegra FXT. The product should not be used in men under 18 years of age. In addition, men over 65 years of age should consult a doctor before taking the drug, as there may be certain contraindications related to their age. This drug improves the love life of such men and maintains their relationship with their partner. The sildenafil citrate used in this drug removes the blockage caused in the corridors and veins and builds up the blood flow to the male organ thereby, strengthening hard and solid erections for longer periods of time.

Malegra ftx is a combination drug. It consists of the well-known sildenafil citrate, the main ingredient in most erectile dysfunction treatments, and fluoxetine, a selective serotonin reuptake inhibitor. Fluoxetine is used as a mild antidepressant, but it has also proven to be an effective solution for premature ejaculation. The combination of these two drugs has made malegra fxt (sildenafil, fluoxetine tablets) one of the best solutions for long-term sexual activity.

Side effects.

Headache

Upset stomach

Drop in blood pressure

Change in color perception

Flushing of the face

Dizziness

Nausea

Headache

A patient who will be treated with this drug should investigate a previous history to diagnose erectile dysfunction and potential risks. The use of this drug should be restricted to patients requiring clinical treatment based on such an objective diagnosis.

Since sexual activity is associated with a risk of heart disease, attention should be paid to cardiovascular conditions before starting treatment. This medicine has a blood pressure lowering effect through its vasodilating effect and may therefore potentiate the blood pressure lowering effect of a nitrate or nitric oxide donor.

Patients who have experienced a cerebral infarction, cerebral haemorrhage or myocardial infarction in the last 6 months should not be administered. When they are given to patients who have had a cerebral infarction, cerebral haemorrhage or myocardial infarction.